The 2021 American Headache Society Guidelines on the Principles of Preventive Migraine Treatment include:

1. using evidence-based treatments


2. titrating until clinical benefits are achieved


3. giving each treatment a trial of at least 2–3 months


4. avoiding overuse of acute treatments

Titration is not necessary with injectable preventive treatments, which are initiated at therapeutic doses and have a relatively rapid onset of action. Furthermore, it states that patients who have severe, disabling, or frequent migraine attacks, as well as those who cannot tolerate or are nonresponsive to acute treatment, should be considered for preventive treatment.

The decision to initiate preventive treatment should be based on:

• the frequency of migraine attacks


• average number of days with migraine


• moderate/severe headache


• degree of disability 

What are the key factors that lead you to initiate migraine prophylaxis?

How do CGRPs fit into your treatment algorithm?

Reference:

1. Ailani J, et al. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain 61:1021-1039.

The 2021 American Headache Society Guidelines on the Principles of Preventive Migraine Treatment include:

1. using evidence-based treatments


2. titrating until clinical benefits are achieved


3. giving each treatment a trial of at least 2–3 months


4. avoiding overuse of acute treatments

Titration is not necessary with injectable preventive treatments, which are initiated at therapeutic doses and have a relatively rapid onset of action. Furthermore, it states that patients who have severe, disabling, or frequent migraine attacks, as well as those who cannot tolerate or are nonresponsive to acute treatment, should be considered for preventive treatment.

The decision to initiate preventive treatment should be based on:

• the frequency of migraine attacks


• average number of days with migraine


• moderate/severe headache


• degree of disability 

What are the key factors that lead you to initiate migraine prophylaxis?

How do CGRPs fit into your treatment algorithm?

Reference:

1. Ailani J, et al. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain 61:1021-1039.

The 2021 American Headache Society Guidelines on the Principles of Preventive Migraine Treatment include:

1. using evidence-based treatments
2. titrating until clinical benefits are achieved
3. giving each treatment a trial of at least 2–3 months
4. avoiding overuse of acute treatments

Titration is not necessary with injectable preventive treatments, which are initiated at therapeutic doses and have a relatively rapid onset of action. Furthermore, it states that patients who have severe, disabling, or frequent migraine attacks, as well as those who cannot tolerate or are nonresponsive to acute treatment, should be considered for preventive treatment.

The decision to initiate preventive treatment should be based on:

• the frequency of migraine attacks
• average number of days with migraine
• moderate/severe headache
• degree of disability 

What are the key factors that lead you to initiate migraine prophylaxis?

How do CGRPs fit into your treatment algorithm?

Reference:

1. Ailani J, et al. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain 61:1021-1039.

The 2021 American Headache Society Guidelines on the Principles of Preventive Migraine Treatment include:

1. using evidence-based treatments


2. titrating until clinical benefits are achieved


3. giving each treatment a trial of at least 2–3 months


4. avoiding overuse of acute treatments

Titration is not necessary with injectable preventive treatments, which are initiated at therapeutic doses and have a relatively rapid onset of action. Furthermore, it states that patients who have severe, disabling, or frequent migraine attacks, as well as those who cannot tolerate or are nonresponsive to acute treatment, should be considered for preventive treatment.

The decision to initiate preventive treatment should be based on:

• the frequency of migraine attacks


• average number of days with migraine


• moderate/severe headache


• degree of disability 

What are the key factors that lead you to initiate migraine prophylaxis?

How do CGRPs fit into your treatment algorithm?

Reference:

1. Ailani J, et al. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain 61:1021-1039.